Gilead Sciences
GILD
$0.29 (-0.39%)
1D
1W
3M
1Y
5Y
ALL
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
The Motley Fool • 2 days ago • GILD
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Zacks Investment Research • 3 days ago • GILD
Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
Business Wire • 5 days ago • GILD
Kite's Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Seeking Alpha • 11 days ago • GILD
Gilead Sciences, Inc. (GILD) Management Presents at Morgan Stanley 21st Annual Global Healthcare Brokers Conference 2023 (Transcript)
Zacks Investment Research • 12 days ago • GILD
Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.
